Latest Æterna Zentaris Stories
All amounts are in U.S. dollars (unless otherwise noted) QUEBEC CITY, March 21, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug development company specializing in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2012. Key Developments in 2012 AEZS-108 (Doxorubicin Peptide Conjugate) -- Special Protocol Assessment...
QUEBEC CITY, March 12, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2012 financial and operating results on Thursday, March 21, 2013, after market close. The Company will host a conference call the next morning, Friday, March 22, 2013 at 8:30 a.m. (Eastern Time), to discuss these results. Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom"...
QUEBEC CITY, March 11, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that an independent Data Safety Monitoring Board ("DSMB") has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade(®)) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. Based on the outcome of its pre-planned interim analysis...
NEW YORK, January 30, 2013 /PRNewswire/ -- Today, Traders Insight announced new research reports highlighting Immunomedics, Inc. (Nasdaq: IMMU), AEterna Zentaris Inc. (Nasdaq: AEZS), Rediff.com India Limited (Nasdaq: REDF), Century Aluminum Co. (Nasdaq: CENX) and Silicom Limited (Nasdaq: SILC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Immunomedics, Inc. Research...
QUÉBEC CITY, Dec. 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable...
Promising clinical response activity observed in patients with Hodgkin lymphoma QUÉBEC CITY, Dec. 11, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin...
QUÉBEC CITY, Dec. 4, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will be presenting a corporate overview at the Oppenheimer 23(rd) Annual Healthcare Conference on Thursday, December 13, 2012, at 9:25 am (Eastern), in the East Foyer of The Waldorf-Astoria Hotel in New York City. A live webcast of this presentation will be available on Aeterna...
QUÉBEC CITY, Nov. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) today announced that final Phase 2 data for perifosine, its oral AKT inhibitor, combined with sorafenib in patients with relapsed/refractory lymphomas, will be presented at the upcoming American Society of Hematology ("ASH") annual meeting in Atlanta, Georgia, December 8-11, 2012. Data will be disclosed during a poster presentation by Anna Guidetti, MD, of the Fondazione IRCCS Instituto...
QUÉBEC CITY, Nov. 19, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG"). Data were presented over the weekend by Thomas J. Kaley, MD, Director, Neuro-Oncology Fellowship Program at Memorial Sloan-Kettering Cancer Center, during a...
All amounts are in U.S. dollars QUEBEC CITY, Nov. 13, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2012. Highlights Perifosine (Oral Akt Inhibitor) -- The Company increased its focus on patient recruitment for...
